Joseph T Coyle

List of Publications by Year
in descending order

305 papers	38,828 citations	4351 88 h-index	2872 190 g-index
326 all docs	326 docs citations	326 times ranked	22908 citing authors

#	Article	IF	Citations
1	Passing the torch: The ascendance of the glutamatergic synapse in the pathophysiology of schizophrenia. Biochemical Pharmacology, 2024, , 116376.	4.6	0
2	Serine Racemase Expression by Striatal Neurons. Cellular and Molecular Neurobiology, 2022, 42, 279-289.	3.3	7
3	Impact of schizophrenia GWAS loci converge onto distinct pathways in cortical interneurons vs glutamatergic neurons during development. Molecular Psychiatry, 2022, 27, 4218-4233.	8.2	7
4	Factors regulating serine racemase and d-amino acid oxidase expression in the mouse striatum. Brain Research, 2021, 1751, 147202.	2.3	3
5	In memoriamâ€"Alan Ivan Green, MD (1943â€"2020). Neuropsychopharmacology, 2021, 46, 1058-1059.	5.6	0
6	Altered neural oscillations and behavior in a genetic mouse model of NMDA receptor hypofunction. Scientific Reports, 2021, 11, 9031.	3.4	16
7	Dopaminergic neuromodulation of prefrontal cortex activity requires the NMDA receptor coagonist <scp>d</scp> -serine. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.6	16
8	Clinical evidence that a dysregulated master neural network modulator may aid in diagnosing schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.6	7
9	iPSC-derived homogeneous populations of developing schizophrenia cortical interneurons have compromised mitochondrial function. Molecular Psychiatry, 2020, 25, 2873-2888.	8.2	57
10	The Discovery and Characterization of Targeted Perikaryal-Specific Brain Lesions With Excitotoxins. Frontiers in Neuroscience, 2020, 14, 927.	2.9	6
11	Activated microglia cause metabolic disruptions in developmental cortical interneurons that persist in interneurons from individuals with schizophrenia. Nature Neuroscience, 2020, 23, 1352-1364.	14.5	53
12	Fifty Years of Research on Schizophrenia: The Ascendance of the Glutamatergic Synapse. American Journal of Psychiatry, 2020, 177, 1119-1128.	8.7	46
13	d-Serine, the Shape-Shifting NMDA Receptor Co-agonist. Neurochemical Research, 2020, 45, 1344-1353.	3.3	40
14	Electroretinographic Abnormalities and Sex Differences Detected with Mesopic Adaptation in a Mouse Model of Schizophrenia: A and B Wave Analysis. , 2020, 61, 16.		5
15	Postsynaptic Serine Racemase Regulates NMDA Receptor Function. Journal of Neuroscience, 2020, 40, 9564-9575.	3.8	33
16	Dysregulated protocadherin-pathway activity as an intrinsic defect in induced pluripotent stem cellâ€"derived cortical interneurons from subjects with schizophrenia. Nature Neuroscience, 2019, 22, 229-242.	14.5	88
17	Investigating brain <scp>d</scp>â€serine: Advocacy for good practices. Acta Physiologica, 2019, 226, e13257.	3.9	26
18	Glutamate hypothesis in schizophrenia. Psychiatry and Clinical Neurosciences, 2019, 73, 204-215.	2.3	255

#	Article	IF	Citations
19	Neurotoxic astrocytes express the d-serine synthesizing enzyme, serine racemase, in Alzheimer's disease. Neurobiology of Disease, 2019, 130, 104511.	4.5	53
20	Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene. Biological Psychiatry, 2019, 86, 523-535.	1.3	35
21	Nâ€Methylâ€<scp>d</scp>â€aspartate receptor coâ€agonist availability affects behavioral and neurochemical responses to cocaine: insights into comorbid schizophrenia and substance abuse. Addiction Biology, 2019, 24, 40-50.	2.7	19
22	Astrocytes in primary cultures express serine racemase, synthesize d -serine and acquire A1 reactive astrocyte features. Biochemical Pharmacology, 2018, 151, 245-251.	4.6	46
23	Location matters: distinct DNA methylation patterns in GABAergic interneuronal populations from separate microcircuits within the human hippocampus. Human Molecular Genetics, 2018, 27, 254-265.	3.0	6
24	Serine Racemase and D-serine in the Amygdala Are Dynamically Involved in Fear Learning. Biological Psychiatry, 2018, 83, 273-283.	1.3	33
25	InÂVivo Brain Glycine and Glutamate Concentrations in Patients With First-Episode Psychosis Measured by Echo Timeâ€“Averaged Proton Magnetic Resonance Spectroscopy at 4T. Biological Psychiatry, 2018, 83, 484-491.	1.3	34
26	Altered CREB Binding to Activity-Dependent Genes in Serine Racemase Deficient Mice, a Mouse Model of Schizophrenia. ACS Chemical Neuroscience, 2018, 9, 2205-2209.	3.7	2
27	Dysbindin-1 contributes to prefrontal cortical dendritic arbor pathology in schizophrenia. Schizophrenia Research, 2018, 201, 270-277.	2.1	18
28	The Role of Serine Racemase in the Pathophysiology of Brain Disorders. Advances in Pharmacology, 2018, 82, 35-56.	3.4	39
29	Probing the lithium-response pathway in hiPSCs implicates the phosphoregulatory set-point for a cytoskeletal modulator in bipolar pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4462-E4471.	7.6	132
30	Cortical Pyramidal Neurons Show a Selective Loss of New Synapses in Chronic Schizophrenia. American Journal of Psychiatry, 2017, 174, 510-511.	8.7	5
31	Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia. Molecular Psychiatry, 2017, 22, 936-943.	8.2	297
32	Astroglial Versus Neuronal D-Serine: Check Your Controls!. Trends in Neurosciences, 2017, 40, 520-522.	8.8	46
33	Schizophrenia: Basic and Clinical. Advances in Neurobiology, 2017, 15, 255-280.	0.0	30
34	Modeling schizophrenia pathogenesis using patient-derived induced pluripotent stem cells (iPSCs). Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 2382-2387.	3.8	24
35	Enhanced astrocytic d-serine underlies synaptic damage after traumatic brain injury. Journal of Clinical Investigation, 2017, 127, 3114-3125.	8.2	104
36	EphB3 signaling propagates synaptic dysfunction in the traumatic injured brain. Neurobiology of Disease, 2016, 94, 73-84.	4.5	30

#	Article	IF	Citations
37	Serine Racemase in Inhibitory Neurons at Striatum and it Might be Involved in Schizophrenia's Pathophysiology with d1 and d2 Receptors. European Psychiatry, 2016, 33, S467-S467.	0.2	0
38	The Rise and Fall of the d -Serine-Mediated Gliotransmission Hypothesis. Trends in Neurosciences, 2016, 39, 712-721.	8.8	166
39	Endogenous co-agonists of the NMDA receptor modulate contextual fear in trace conditioning. Neurobiology of Learning and Memory, 2016, 136, 244-250.	2.0	7
40	d-Serine and the Pathophysiology of Schizophrenia. , 2016, , 101-118.		3
41	Glutamatergic Dysfunction in Schizophrenia Evaluated With Magnetic Resonance Spectroscopy. JAMA Psychiatry, 2016, 73, 649.	11.4	4
42	History of the Concept of Disconnectivity in Schizophrenia. Harvard Review of Psychiatry, 2016, 24, 80-86.	2.2	41
43	Touchscreen assays of learning, response inhibition, and motivation in the marmoset (Callithrix) Tj ETQq1 1 0.784314 rgBT /Overlock	1.8	20
44	An mGlu5-Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia. Neuropsychopharmacology, 2016, 41, 2052-2061.	5.6	61
45	Availability of N-Methyl-d-Aspartate Receptor Coagonists Affects Cocaine-Induced Conditioned Place Preference and Locomotor Sensitization: Implications for Comorbid Schizophrenia and Substance Abuse. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 465-470.	2.4	16
46	Altered prefrontal cortical MARCKS and PPP1R9A mRNA expression in schizophrenia and bipolar disorder. Schizophrenia Research, 2015, 164, 100-108.	2.1	28
47	Subchronic pharmacological and chronic genetic NMDA receptor hypofunction differentially regulate the Akt signaling pathway and Arc expression in juvenile and adult mice. Schizophrenia Research, 2015, 162, 216-221.	2.1	13
48	The NMDA receptor â€˜glycine modulatory siteâ€™ in schizophrenia: d-serine, glycine, and beyond. Current Opinion in Pharmacology, 2015, 20, 109-115.	3.6	178
49	Possible Compensatory Mechanisms for Glutamatergic Disconnection Found in the Auditory Cortex in Schizophrenia. Biological Psychiatry, 2015, 77, 923-924.	1.3	2
50	Neuronal serine racemase regulates extracellular d-serine levels in the adult mouse hippocampus. Journal of Neural Transmission, 2015, 122, 1099-1103.	2.9	25
51	Global Biochemical Profiling Identifies Î²-Hydroxypyruvate as a Potential Mediator of Type 2 Diabetes in Mice and Humans. Diabetes, 2015, 64, 1383-1394.	0.9	19
52	In vivo magnetic resonance studies reveal neuroanatomical and neurochemical abnormalities in the serine racemase knockout mouse model of schizophrenia. Neurobiology of Disease, 2015, 73, 269-274.	4.5	28
53	d-Serine and Serine Racemase are Localized to Neurons in the Adult Mouse and Human Forebrain. Cellular and Molecular Neurobiology, 2014, 34, 419-435.	3.3	109
54	Prefrontal Cortical Dendritic Spine Pathology in Schizophrenia and Bipolar Disorder. JAMA Psychiatry, 2014, 71, 1323.	11.4	323

#	Article	IF	Citations
55	D-serine deficiency attenuates the behavioral and cellular effects induced by the hallucinogenic 5-HT2A receptor agonist DOI. Behavioural Brain Research, 2014, 259, 242-246.	2.3	7
56	Chronic D-serine reverses arc expression and partially rescues dendritic abnormalities in a mouse model of NMDA receptor hypofunction. Neurochemistry International, 2014, 75, 76-78.	3.9	37
57	Time-dependent effects of haloperidol on glutamine and GABA homeostasis and astrocyte activity in the rat brain. Psychopharmacology, 2013, 230, 57-67.	3.1	15
58	Nitric Oxide and Symptom Reduction in Schizophrenia. JAMA Psychiatry, 2013, 70, 664.	11.4	15
59	Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2400-9.	7.6	190
60	Glutamate Carboxypeptidase II. , 2013, , 1620-1627.		6
61	Brain Structural Alterations Induced by Fetal Exposure to Cocaine Persist Into Adolescence and Affect Behavior. JAMA Psychiatry, 2013, 70, 1113.	11.4	2
62	Identity of endogenous NMDAR glycine site agonist in amygdala is determined by synaptic activity level. Nature Communications, 2013, 4, 1760.	13.2	75
63	Much More Than a Name Change. JAMA Psychiatry, 2013, 70, 8.	11.4	4
64	Relapse in Alcohol Use Disorderâ€”Reply. JAMA Psychiatry, 2013, 70, 1248.	11.4	0
65	NAAG, NMDA Receptor and Psychosis. Current Medicinal Chemistry, 2012, 19, 1360-1364.	2.5	41
66	Altered Acquisition and Extinction of Amphetamine-Paired Context Conditioning in Genetic Mouse Models of Altered NMDA Receptor Function. Neuropsychopharmacology, 2012, 37, 2496-2504.	5.6	20
67	Changes in JAMA and the Archives of General Psychiatry. Archives of General Psychiatry, 2012, 69, 447.	13.2	1
68	NMDA Receptor and Schizophrenia: A Brief History. Schizophrenia Bulletin, 2012, 38, 920-926.	4.6	346
69	Neuronal d-serine regulates dendritic architecture in the somatosensory cortex. Neuroscience Letters, 2012, 517, 77-81.	2.1	44
70	Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications. Handbook of Experimental Pharmacology, 2012, , 267-295.	0.0	153
71	The JAMA Network Journals. Archives of Neurology, 2012, 69, 817.	4.5	0
72	The Neurochemistry of Schizophrenia. , 2012, , 1000-1011.		1

#	Article	IF	Citations
73	Cell Selective Conditional Null Mutations of Serine Racemase Demonstrate a Predominate Localization in Cortical Glutamatergic Neurons. Cellular and Molecular Neurobiology, 2012, 32, 613-624.	3.3	132
74	Glutamate carboxypeptidase II and folate deficiencies result in reciprocal protection against cognitive and social deficits in mice: Implications for neurodevelopmental disorders. Developmental Neurobiology, 2012, 72, 891-905.	3.1	17
75	The NMDA receptor co-agonists, d-serine and glycine, regulate neuronal dendritic architecture in the somatosensory cortex. Neurobiology of Disease, 2012, 45, 671-682.	4.5	82
76	Glutamatergic Synaptic Dysregulation in Schizophrenia. , 2012, , 115-142.		1
77	Failure of NMDA receptor hypofunction to induce a pathological reduction in PV-positive GABAergic cell markers. Neuroscience Letters, 2011, 488, 267-271.	2.1	29
78	Serine racemase deletion abolishes lightâ€evoked NMDA receptor currents in retinal ganglion cells. Journal of Physiology, 2011, 589, 5997-6006.	2.9	20
79	Glutamate receptor composition of the post-synaptic density is altered in genetic mouse models of NMDA receptor hypo- and hyperfunction. Brain Research, 2011, 1392, 1-7.	2.3	32
80	Discordant behavioral effects of psychotomimetic drugs in mice with altered NMDA receptor function. Psychopharmacology, 2011, 213, 143-153.	3.1	13
81	Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neuroscience and Biobehavioral Reviews, 2011, 35, 848-870.	6.6	148
82	Serine Racemase Deletion Protects Against Cerebral Ischemia and Excitotoxicity. Journal of Neuroscience, 2010, 30, 1413-1416.	3.8	94
83	Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia. Dialogues in Clinical Neuroscience, 2010, 12, 359-382.	4.7	63
84	MicroRNAs suggest a new mechanism for altered brain gene expression in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2975-2976.	7.6	27
85	Phenotypic characterization of mice heterozygous for a null mutation of glutamate carboxypeptidase II. Synapse, 2009, 63, 625-635.	1.3	25
86	The Role of Animal Models in Evaluating Reasonable Safety and Efficacy for Human Trials of Cell-Based Interventions for Neurologic Conditions. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 1-9.	4.6	34
87	The glycine transporter GlyT1 controlsNâ€methylâ€Dâ€aspartic acid receptor coagonist occupancy in the mouse retina. European Journal of Neuroscience, 2009, 30, 2308-2317.	3.5	18
88	Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends in Neurosciences, 2008, 31, 234-242.	8.8	914
89	Science and Psychiatry: Groundbreaking Discoveries in Molecular Neuroscienceby Solomon H. Snyder, M.D. Arlington, Va, American Psychiatric Publishing, 2008, 513 pp., $65.00.. American Journal of Psychiatry, 2008, 165, 1492-1493.	8.7	1
90	Psychiatric Neuroscience: Incorporating Pathophysiology into Clinical Case Formulation. , 2008, , 543-564.		1

#	Article	IF	Citations
91	What can a clock mutation in mice tell us about bipolar disorder?. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6097-6098.	7.6	17
92	Low Cerebrospinal Fluid Glutamate and Glycine in Refractory Affective Disorder. Biological Psychiatry, 2007, 61, 162-166.	1.3	140
93	Beyond In Vitro Data: A Review of In Vivo Evidence Regarding the Allosteric Potentiating Effect of Galantamine on Nicotinic Acetylcholine Receptors in Alzheimer's Neuropathology. Journal of Alzheimer's Disease, 2007, 11, 491-507.	2.7	28
94	Endogenous N-acetylaspartylglutamate reduced NMDA receptor-dependent current neurotransmission in the CA1 area of the hippocampus. Journal of Neurochemistry, 2007, 100, 346-357.	4.0	37
95	Promoter analysis of human glutamate carboxypeptidase II. Brain Research, 2007, 1170, 1-12.	2.3	4
96	Ube3a mRNA and protein expression are not decreased in Mecp2 mutant mice. Brain Research, 2007, 1180, 1-6.	2.3	68
97	Glial metabolites of tryptophan and excitotoxicity: Coming unglued. Experimental Neurology, 2006, 197, 4-7.	4.1	13
98	Neurobiology of Schizophrenia. Neuron, 2006, 52, 139-153.	8.0	624
99	Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis. Cellular and Molecular Neurobiology, 2006, 26, 363-382.	3.3	788
100	Substance use disorders and schizophrenia: A question of shared glutamatergic mechanisms. Neurotoxicity Research, 2006, 10, 221-233.	2.7	69
101	A Brief Overview of N-Acetylaspartate and N-Acetylaspartylglutamate. , 2006, 576, 1-6.		2
102	Reduced glycine transporter type 1 expression leads to major changes in glutamatergic neurotransmission of CA1 hippocampal neurones in mice. Journal of Physiology, 2005, 563, 777-793.	2.9	46
103	Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of d-cycloserine. Psychiatry Research - Neuroimaging, 2005, 138, 23-31.	1.9	43
104	Do Maternal Folate and Homocysteine Levels Play a Role in Neurodevelopmental Processes That Increase Risk for Schizophrenia?. Harvard Review of Psychiatry, 2005, 13, 197-205.	2.2	64
105	NAAG Reduces NMDA Receptor Current in CA1 Hippocampal Pyramidal Neurons of Acute Slices and Dissociated Neurons. Neuropsychopharmacology, 2005, 30, 7-16.	5.6	60
106	Gene knockout of glycine transporter 1: Characterization of the behavioral phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8485-8490.	7.6	193
107	NMDA Receptor Function, Neuroplasticity, and the Pathophysiology of Schizophrenia. International Review of Neurobiology, 2004, 59, 491-515.	1.8	116
108	Glutamate Carboxypeptidase II Gene Expression in the Human Frontal and Temporal Lobe in Schizophrenia. Neuropsychopharmacology, 2004, 29, 117-125.	5.6	45

#	Article	IF	Citations
109	Decoding Schizophrenia. Scientific American, 2004, 290, 48-55.	0.0	25
110	The GABA-glutamate connection in schizophrenia: which is the proximate cause?. Biochemical Pharmacology, 2004, 68, 1507-1514.	4.6	173
111	The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology, 2004, 174, 32-8.	3.1	201
112	The demise of old certitudes and the birth of novel opportunities in neuropsychopharmacology. Current Opinion in Pharmacology, 2004, 4, 1-3.	3.6	9
113	Glutamate carboxypeptidase II. , 2004, , 960-963.		0
114	Finding the Intracellular Signaling Pathways Affected by Mood Disorder Treatments. Neuron, 2003, 38, 157-160.	8.0	356
115	Use It or Lose It â€" Do Effortful Mental Activities Protect against Dementia?. New England Journal of Medicine, 2003, 348, 2489-2490.	30.1	73
116	Regulation of Glutamate Carboxypeptidase II Function in Corticolimbic Regions of Rat Brain by Phencyclidine, Haloperidol, and Clozapine. Neuropsychopharmacology, 2003, 28, 1227-1234.	5.6	25
117	Glutamatergic Mechanisms in Schizophrenia. Annual Review of Pharmacology and Toxicology, 2002, 42, 165-179.	9.6	571
118	Insulin-Like Growth Factor I Prevents the Development of Sensitivity to Kainate Neurotoxicity in Cerebellar Granule Cells. Journal of Neurochemistry, 2002, 75, 1548-1556.	4.0	13
119	Mice Transgenic for Copper/Zinc Superoxide Dismutase Exhibit Increased Markers of Biogenic Amine Function. Journal of Neurochemistry, 2002, 65, 660-669.	4.0	3
120	L-type calcium channels reduce ROS generation in cerebellar granule cells following kainate exposure. Synapse, 2002, 43, 30-41.	1.3	12
121	Getting balance: Drugs for bipolar disorder share target. Nature Medicine, 2002, 8, 557-558.	30.1	28
122	Treating a Child With Aspergerâ€™s Disorder and Comorbid Bipolar Disorder. American Journal of Psychiatry, 2002, 159, 13-21.	8.7	50
123	Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimerâ€™s disease. Biological Psychiatry, 2001, 49, 289-299.	1.3	321
124	Chapter 1: Same brain, new decade: Challenges in CNS drug discovery in the postgenomic, proteomic era. Annual Reports in Medicinal Chemistry, 2001, 36, 1-10.	0.8	10
125	Drug Treatment of Anxiety Disorders in Children. New England Journal of Medicine, 2001, 344, 1326-1327.	30.1	20
126	The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia. American Journal of Psychiatry, 2001, 158, 1367-1377.	8.7	843

#	Article	IF	Citations
127	Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET. Synapse, 2000, 36, 57-65.	1.3	82
128	Intracellular Modulation of NMDA Receptor Function by Antipsychotic Drugs. Journal of Neuroscience, 2000, 20, 4011-4020.	3.8	149
129	Mind Glue. Archives of General Psychiatry, 2000, 57, 90.	13.2	108
130	Psychotropic Drug Use in Very Young Children. JAMA - Journal of the American Medical Association, 2000, 283, 1059.	7.0	84
131	Short-term and Long-term Effects of N-Methyl-D-Aspartate Receptor Hypofunction. Archives of General Psychiatry, 2000, 57, 1180.	13.2	10
132	Ice-Nine and Human Prion Disease. Harvard Review of Psychiatry, 1999, 6, 331-333.	2.2	2
133	Site-Directed Mutagenesis of Predicted Active Site Residues in Glutamate Carboxypeptidase II. Molecular Pharmacology, 1999, 55, 179-185.	2.3	57
134	L-type voltage-gated calcium channels modulate kainic acid neurotoxicity in cerebellar granule cells. Brain Research, 1999, 828, 27-40.	2.3	36
135	Glutamate carboxypeptidase II is expressed by astrocytes in the adult rat nervous system. Journal of Comparative Neurology, 1999, 415, 52-64.	2.0	103
136	A Placebo-Controlled Trial of D-Cycloserine Added to Conventional Neuroleptics in Patients With Schizophrenia. Archives of General Psychiatry, 1999, 56, 21.	13.2	412
137	Effects of over- and under-expression of Cu,Zn-superoxide dismutase on the toxicity of glutamate analogs in transgenic mouse striatum. Brain Research, 1998, 789, 32-39.	2.3	51
138	Hydrolysis of the neuropeptide N-acetylaspartylglutamate (NAAG) by cloned human glutamate carboxypeptidase II. Brain Research, 1998, 795, 341-348.	2.3	49
139	Effects of overexpression of the cytoplasmic copper-zinc superoxide dismutase on the survival of neurons in vitro. Synapse, 1998, 29, 206-212.	1.3	12
140	Somatostatin expression in TS16 mouse brain cultures. Journal of Molecular Neuroscience, 1998, 10, 99-111.	2.4	2
141	Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biological Psychiatry, 1998, 44, 667-674.	1.3	73
142	D-serine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry, 1998, 44, 1081-1089.	1.3	590
143	The Role of Glutamatergic Neurotransmission in the Pathophysiology of Alcoholism. Annual Review of Medicine, 1998, 49, 173-184.	12.2	383
144	Folylpoly-Î³-glutamate Carboxypeptidase from Pig Jejunum. Journal of Biological Chemistry, 1998, 273, 20417-20424.	3.5	101

#	Article	IF	Citations
145	Markers of Glutamatergic Neurotransmission and Oxidative Stress Associated With Tardive Dyskinesia. American Journal of Psychiatry, 1998, 155, 1207-1213.	8.7	236
146	The Nagging Question of the Function ofN-Acetylaspartylglutamate. Neurobiology of Disease, 1997, 4, 231-238.	4.5	163
147	N-Acetylaspartylglutamate (NAAG) protects against rat striatal quinolinic acid lesions in vivo. Neuroscience Letters, 1997, 236, 91-94.	2.1	34
148	Distribution of N-acetylaspartylglutamate immunoreactivity in human brain and its alteration in neurodegenerative disease. Brain Research, 1997, 772, 9-22.	2.3	42
149	N-acetylaspartylglutamate,N-acetylaspartate, andN-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer diseases. Molecular and Chemical Neuropathology, 1997, 31, 97-118.	1.0	64
150	The Glutamatergic Dysfunction Hypothesis for Schizophrenia. Harvard Review of Psychiatry, 1996, 3, 241-253.	2.2	530
151	N-acetylated alpha-linked acidic dipeptidase is expressed by non-myelinating Schwann cells in the peripheral nervous system. Journal of Neurocytology, 1995, 24, 99-109.	1.4	56
152	N -Acetylaspartate in neuropsychiatric disorders. Progress in Neurobiology, 1995, 46, 531-540.	5.8	398
153	The Neuroscience Perspective and the Changing Role of the Psychiatrist. Academic Psychiatry, 1995, 19, 202-212.	0.7	6
154	Funding of NIMH extramural research. Science, 1994, 264, 1517-1517.	20.9	1
155	Cholinergic innervation of mouse forebrain structures. Journal of Comparative Neurology, 1994, 341, 117-129.	2.0	102
156	Developmental regulation of adult cortical morphology and behavior: An animal model for mental retardation. International Journal of Developmental Neuroscience, 1994, 12, 239-253.	1.6	42
157	Kainic acid-induced lipid peroxidation: protection with butylated hydroxytoluene and U78517F in primary cultures of cerebellar granule cells. Brain Research, 1993, 624, 223-232.	2.3	101
158	Abnormal acidic amino acids and N-acetylaspartylglutamate in hereditary canine motoneuron disease. Brain Research, 1993, 629, 305-309.	2.3	14
159	Immunocytochemical distribution of n-acetylaspartylglutamate in the rat forebrain and glutamatergic pathways. Journal of Chemical Neuroanatomy, 1993, 6, 277-292.	2.2	32
160	Dissociation of nitric oxide generation and kainate-mediated neuronal degeneration in primary cultures of rat cerebellar granule cells. Neuropharmacology, 1992, 31, 565-575.	4.2	45
161	Genetically epilepsy-prone rats have increased brain regional activity of an enzyme which liberates glutamate from N-acetyl-aspartyl-glutamate. Brain Research, 1992, 593, 140-143.	2.3	37
162	Brain Serotonin2and Serotonin1AReceptors Are Altered in the Congenitally Hyperammonemic Sparse Fur Mouse. Journal of Neurochemistry, 1992, 58, 1016-1022.	4.0	39

#	Article	IF	Citations
163	Immunocytochemical localization of the N-acetyl-aspartyl-glutamate (NAAG) hydrolyzing enzyme N-acetylated ?-linked acidic dipeptidase (NAALADase). Journal of Comparative Neurology, 1992, 315, 217-229.	2.0	91
164	Kindling increases brain levels of NAAG and seizures reduce activity of a NAAG-hydrolyzing enzyme, NAALADase. , 1992, 8, 297-305.		3
165	Glutamate Neurotoxicity and the Inhibition of Protein Synthesis in the Hippocampal Slice. Journal of Neurochemistry, 1991, 56, 996-1006.	4.0	69
166	The Potential for Muscarinic Receptor Subtype-Specific Pharmacotherapy for Alzheimer's Disease. Mayo Clinic Proceedings, 1991, 66, 1225-1237.	2.8	76
167	Reductions in acidic amino acids andN-acetylaspartylglutamate in amyotrophic lateral sclerosis CNS. Brain Research, 1991, 556, 151-156.	2.3	106
168	Enhancement of NMDA receptor-mediated neurotoxicity in the hippocampal slice by depolarization and ischemia. Brain Research, 1991, 555, 99-106.	2.3	43
169	Effects of calmodulin antagonists on sodium-dependent high-affinity choline uptake. Brain Research, 1991, 542, 132-134.	2.3	8
170	Enhanced NAD(P)H:Quinone Reductase Activity Prevents Glutamate Toxicity Produced by Oxidative Stress. Journal of Neurochemistry, 1991, 56, 990-995.	4.0	76
171	Excitatory amino acids in amyotrophic lateral sclerosis: An update. Annals of Neurology, 1991, 30, 224-225.	5.8	95
172	Developmental expression of the gene encoding growth-associated protein 43(GAP43) in the brains of normal and aneuploid mice. Journal of Neuroscience Research, 1991, 29, 449-460.	3.0	12
173	Platelet serotonin, a possible marker for familial autism. Journal of Autism and Developmental Disorders, 1991, 21, 51-59.	3.1	134
174	In Reply: Neuroleptic Malignant Syndrome. Pediatrics, 1991, 88, 1074-1074.	2.2	3
175	Effects of different doses of galanthamine, a long-acting acetylcholinesterase inhibitor, on memory in mice. Psychopharmacology, 1990, 102, 191-200.	3.1	74
176	Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Annals of Neurology, 1990, 28, 18-25.	5.8	607
177	Glutamate induced neuronal degeneration and oxidative stress. The Japanese Journal of Pharmacology, 1990, 52, 4.	1.2	0
178	Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. FASEB Journal, 1990, 4, 1624-1633.	0.5	399
179	Increased number of somatostatin-immunoreactive neurons in primary cultures of Trisomy 16 mouse neocortex. Molecular Brain Research, 1990, 7, 269-272.	2.4	11
180	Chapter 23 Transplantation of brain tissue from murine trisomy 16 into euploid hosts: Effects of gene imbalance on brain development. Progress in Brain Research, 1990, 82, 203-214.	3.9	9

#	Article	IF	Citations
181	Developmental expression of somatostatin in mouse brain. I. Immunocytochemical studies. Developmental Brain Research, 1990, 53, 6-25.	1.8	63
182	Developmental expression of somatostatin in mouse brain. II. In situ hybridization. Developmental Brain Research, 1990, 53, 26-39.	1.8	66
183	Galanthamine, an acetylcholinesterase inhibitor: A time course of the effects on performance and neurochemical parameters in mice. Pharmacology Biochemistry and Behavior, 1989, 34, 129-137.	2.8	62
184	Lesions of the basal forebrain alter stimulus-evoked metabolic activity in mouse somatosensory cortex. Journal of Comparative Neurology, 1989, 288, 414-427.	2.0	40
185	The postnatal expression of acetylcholinesterase in somatostatin-positive cells of mouse hippocampus. Developmental Brain Research, 1989, 48, 73-85.	1.8	10
186	Seizures decrease regional enzymatic hydrolysis of N-acetyl-aspartylglutamate in rat brain. Brain Research, 1989, 505, 130-134.	2.3	20
187	Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron, 1989, 2, 1547-1558.	8.0	950
188	The effects of N-acetylated alpha-linked acidic dipeptidase (NAALADase) inhibitors on [3H]NAAG catabolism in vivo. Neuroscience Letters, 1989, 100, 295-300.	2.1	48
189	Development of Î²1 and Î²2 adrenergic receptors in baboon brain: An autoradiographic study using [125I]iodocyanopindolol. Journal of Comparative Neurology, 1988, 273, 318-329.	2.0	23
190	Calcium-Dependent Evoked Release of N[3H]Acetylaspartylglutamate from the Optic Pathway. Journal of Neurochemistry, 1988, 51, 1956-1959.	4.0	67
191	Solubilization and Characterization of a [3H]Hemicholinium-3 Binding Site in Rat Brain. Journal of Neurochemistry, 1988, 50, 1759-1764.	4.0	24
192	Hydrolysis of the Brain Dipeptide N-Acetyl-l-Aspartyl-l-Glutamate: Subcellular and Regional Distribution, Ontogeny, and the Effect of Lesions on N-Acetylated-?-Linked Acidic Dipeptidase Activity. Journal of Neurochemistry, 1988, 50, 1200-1209.	4.0	79
193	A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice. Pharmacology Biochemistry and Behavior, 1988, 31, 141-147.	2.8	75
194	A re-examination of the interaction of N-acetyl-L-aspartyl-L-glutamate with a subpopulation of rat brain membrane L-[3H]glutamate binding sites. European Journal of Pharmacology, 1988, 151, 419-426.	3.6	13
195	Involvement of phospholipase A2 in the regulation of [3H]hemicholinium-3 binding. Biochemical Pharmacology, 1988, 37, 4367-4373.	4.6	20
196	Calcium-dependent glutamate cytotoxicity in a neuronal cell line. Brain Research, 1988, 444, 325-332.	2.3	83
197	The role of calcium in the regulation of [3H]hemicholinium-3 binding sites in rat brain. Neuropharmacology, 1988, 27, 1301-1308.	4.2	21
198	Down syndrome, Alzheimer's disease and the trisomy 16 mouse. Trends in Neurosciences, 1988, 11, 390-394.	8.8	88

#	Article	IF	Citations
199	Quantitation of N-acetyl-aspartyl-glutamate in microdissected rat brain nuclei and peripheral tissues: findings with a novel liquid phase radioimmunoassay. Molecular Brain Research, 1988, 3, 223-231.	2.4	35
200	Long-term effects of basal forebrain lesions on cholinergic, noradrenergic and serotonergic markers in mouse neocortex. Brain Research Bulletin, 1988, 21, 13-20.	3.1	22
201	Cerebrospinal Fluid Correlates of Depression in Huntington's Disease. Archives of Neurology, 1988, 45, 881-883.	4.5	33
202	Effect of Sodium Benzoate and Sodium Phenylacetate on Brain Serotonin Turnover in the Ornithine Transcarbamylase-Deficient Sparse-Fur Mouse. Pediatric Research, 1988, 23, 368-374.	2.4	34
203	The Neurobiology of N-Acetylasparty. International Review of Neurobiology, 1988, , 39-100.	1.8	84
204	Inhibition of [3H]kainic acid receptor binding by divalent cations correlates with ion affinity for the calcium channel. Neuropharmacology, 1987, 26, 1247-1251.	4.2	111
205	Selective immunocytochemical staining of mitral cells in rat olfactory bulb with affinity purified antibodies against N-acetyl-aspartyl-glutamate. Brain Research, 1987, 402, 373-378.	2.3	63
206	The development of daytime rearing behavior in methylazoxymethanol-treated rats: Methodological considerations. Behavioural Brain Research, 1987, 25, 97-100.	2.3	5
207	Age-related recurrence of basal forebrain lesion-induced cholinergic deficits. Neuroscience Letters, 1987, 82, 253-259.	2.1	44
208	Specific alterations in the levels of N-acetyl-aspartyl-glutamate in the nervous system of the dystrophic mouse. Neuroscience Letters, 1987, 79, 223-228.	2.1	12
209	Co-localization of N-acetyl-aspartyl-glutamate in central cholinergic, noradrenergic, and serotonergic neurons. Synapse, 1987, 1, 455-460.	1.3	99
210	Developmental consequences of autosomal aneuploidy in mammals. Genesis, 1987, 8, 249-265.	2.6	28
211	Neurochemical characterization of embryonic brain development in trisomy 19 (Ts19) mice: Implications of selective deficits observed for abnormal neural development in aneuploidy. Genesis, 1987, 8, 267-279.	2.6	18
212	Kainic Acid: Insights into Excitatory Mechanisms Causing Selective Neuronal Degeneration. Novartis Foundation Symposium, 1987, 126, 186-203.	0.0	26
213	Quisqualate selectively inhibits a brain peptisade which cleaves N-acetyl-L-aspartyl-L-glutamate in vitro. European Journal of Pharmacology, 1986, 130, 345-347.	3.6	40
214	Basal forebrain neurons provide major cholinergic innervation of primate neocortex. Neuroscience Letters, 1986, 66, 215-220.	2.1	53
215	Neurotransmitter actions in the vertebrate nervous system. Cell, 1986, 45, 783.	27.8	0
216	Rapid regulation of [3H]hemicholinium-3 binding sites in the rat brain. Brain Research, 1986, 381, 191-194.	2.3	58

#	Article	IF	Citations
217	Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Research, 1986, 371, 146-151.	2.3	541
218	Anatomical predictors of behavioral recovery following fetal striatal transplants. Brain Research, 1986, 365, 249-258.	2.3	127
219	Anorexia and altered serotonin metabolism in a patient with argininosuccinic aciduria. Journal of Pediatrics, 1986, 108, 705-709.	2.2	38
220	Primary Degenerative Dementia Without Alzheimer Pathology. Canadian Journal of Neurological Sciences, 1986, 13, 462-470.	0.6	70
221	Suspected Adverse Methylphenidate-Imipramine Interactions in Children. Journal of Developmental and Behavioral Pediatrics, 1986, 7, 265-267.	1.2	31
222	Cortical Degeneration with Swollen Chromatolytic Neurons. Journal of Neuropathology and Experimental Neurology, 1986, 45, 268-284.	1.8	84
223	Topography of Locomotor Behaviour in the Chick. Bird Behavior, 1986, 6, 93-96.	0.2	1
224	Behavioral and Neurotransmitter Changes in the Urease-Infused Rat: A Model of Congenital Hyperammonemia. Pediatric Research, 1986, 20, 1310-1315.	2.4	38
225	Synaptosomal Transport of Radiolabel from Nâ€Acetylâ€Aspartylâ€[³H]Glutamate Suggests a Mechanism of Inactivation of an Excitatory Neuropeptide. Journal of Neurochemistry, 1986, 47, 1013-1019.	4.0	42
226	Cerebrospinal fluid acetylcholinesterase activity in senile dementia of the Alzheimer type. Annals of Neurology, 1985, 17, 46-48.	5.8	68
227	Basal forebrain lesions produce a dissociation of trial-dependent and trial-independent memory performance. Brain Research, 1985, 345, 315-321.	2.3	113
228	Combined Use of Tricyclic Antidepressants and Neuroleptics in the Management of Terminally 111 Children: A Report on Three Cases. Journal of the American Academy of Child Psychiatry, 1985, 24, 487-489.	0.7	8
229	Excitatory amino acid analogs evoke release of endogenous amino acids and acetyl choline from chick retina in vitro. Vision Research, 1985, 25, 1375-1386.	1.5	29
230	Characterization of [3H]hemicholinium-3 binding associated with neuronal choline uptake sites in rat brain membranes. Brain Research, 1985, 348, 321-330.	2.3	98
231	Regional brain levels of N-acetyl-aspartyl-glutamate: the effect of kindled seizures. Brain Research, 1985, 346, 392-396.	2.3	29
232	Memory impairments following basal forebrain lesions. Brain Research, 1985, 346, 8-14.	2.3	257
233	N-Acetyl-Aspartyl-Glutamate: Regional Levels in Rat Brain and the Effects of Brain Lesions as Determined by a New HPLC Method. Journal of Neurochemistry, 1984, 43, 1136-1142.	4.0	352
234	Decreased Cortical Glucose Utilization after Ibotenate Lesion of the Rat Ventromedial Globus Pallidus. Journal of Cerebral Blood Flow and Metabolism, 1984, 4, 381-390.	4.6	76

#	Article	IF	Citations
235	Parametric influences on catalepsy. Psychopharmacology, 1984, 82, 406-408.	3.1	23
236	Serum neuroleptic concentrations and clinical response: A radioreceptor assay investigation of acutely psychotic patients. Psychopharmacology, 1984, 82, 194-198.	3.1	18
237	Investigating locomotion abnormalities in animal models of extrapyramidal disorders: A commentary. Physiological Psychology, 1984, 12, 48-50.	0.7	18
238	The dissociation of evoked release of [3H]-GABA and of endogenous GABA from chick retina in vitro. Experimental Eye Research, 1984, 39, 299-305.	2.7	18
239	Neurotransmitter specific alterations in dementing disorders: Insights from animal models. Journal of Psychiatric Research, 1984, 18, 501-512.	3.2	13
240	Regional heterogeneity of choline acetyltransferase activity in primate neocortex. Brain Research, 1984, 322, 361-364.	2.3	54
241	Effects of intrastriatal injections of the cholinergic neurotoxin AF64A on spontaneous nocturnal locomotor behavior in the rat. Brain Research, 1984, 299, 339-343.	2.3	28
242	Synaptic Neurochemical Alterations Associated with Neuronal Degeneration in an Inherited Cerebellar Ataxia of Gordon Setters. Journal of Neuropathology and Experimental Neurology, 1984, 43, 580-591.	1.8	11
243	Synaptic Chemistry Associated with Aberrant Neuronal Development in the Reeler Mouse. Journal of Neurochemistry, 1983, 41, 874-881.	4.0	16
244	Topographic analysis of the innervation of the rat neocortex and hippocampus by the basal forebrain cholinergic system. Journal of Comparative Neurology, 1983, 217, 103-121.	2.0	456
245	Evoked release of aspartate and glutamate: disparities between prelabeling and direct measurement. Brain Research, 1983, 278, 279-282.	2.3	40
246	Automated measurement of stereotypic behavior in rats.. Behavioral Neuroscience, 1983, 97, 830-832.	1.2	35
247	Neuroleptic Drug Level Monitoring in Psychiatry. Therapeutic Drug Monitoring, 1982, 4, 59-64.	2.2	18
248	The Clinical Use of Antipsychotic Medications. Medical Clinics of North America, 1982, 66, 993-1009.	2.3	6
249	Somatostatin is not co-localized in cholinergic neurons innervating the rat cerebral cortex-hippocampal formation. Brain Research, 1982, 243, 169-172.	2.3	62
250	Cytotoxic lesions and the development of transmitter systems. Trends in Neurosciences, 1982, 5, 153-156.	8.8	65
251	Neurotoxic amino acids in human degenerative disorders. Trends in Neurosciences, 1982, 5, 287-288.	8.8	19
252	Dopaminergic dysfunction in tourette syndrome. Annals of Neurology, 1982, 12, 361-366.	5.8	184

#	Article	IF	Citations
253	Effects of Kainic Acid on High-Energy Metabolites in the Mouse Striatum. Journal of Neurochemistry, 1982, 38, 196-203.	4.0	47
254	Kainic acid stimulates excitatory amino acid neurotransmitter release at presynaptic receptors. Nature, 1982, 298, 757-759.	36.2	286
255	N-methyl-d-aspartic acid: A convulsant with weak neurotoxic properties. Neuroscience Letters, 1981, 24, 181-186.	2.1	26
256	Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Annals of Neurology, 1981, 10, 122-126.	5.8	1,706
257	Effects of spinal transection on presynaptic markers for glutamatergic neurons in the rat. Neurochemical Research, 1981, 6, 485-496.	3.3	10
258	Acute extrapyramidal side effects: Serum levels of neuroleptics and anticholinergics. Psychopharmacology, 1981, 75, 9-15.	3.1	91
259	Development of Central Neurotransmitter Systems. Novartis Foundation Symposium, 1981, 86, 251-270.	0.0	22
260	Local and Distant Neuronal Degeneration Following Intrastriatal Injection of Kainic Acid. Journal of Neuropathology and Experimental Neurology, 1980, 39, 245-264.	1.8	97
261	Ontogeny of Neurochemical Markers for Noradrenergic, GABAergic and Cholinergic Neurons in Neocortex Lesioned with Methylazoxymethanol Acetate. Journal of Neurochemistry, 1980, 34, 1429-1441.	4.0	113
262	Characterization of specific, high-affinity binding sites for l-[3H]glutamic acid in rat brain membranes. Brain Research, 1980, 183, 421-433.	2.3	105
263	The differential effect of right versus left hemispheric cerebral infarction on catecholamines and behavior in the rat. Brain Research, 1980, 188, 63-78.	2.3	183
264	Phylogenetic distribution of [3H]kainic acid receptor binding sites in neuronal tissue. Brain Research, 1980, 192, 463-476.	2.3	70
265	The development of catecholaminergic innervation in chick spinal cord. Brain Research, 1980, 191, 417-428.	2.3	25
266	Striatal opiate receptors: Pre- and postsynaptic localization. Life Sciences, 1980, 27, 1175-1183.	4.4	94
267	Kainic acid lesion of mouse striatum: Effects on energy metabolites. Life Sciences, 1980, 27, 2495-2500.	4.4	17
268	Head and trunk neural crest in vitro: Autonomic neuron differentiation. Developmental Biology, 1980, 77, 340-348.	2.1	52
269	Effects of cortical ablation on the neurotoxicity and receptor binding of kainic acid in striatum. Journal of Neuroscience Research, 1979, 4, 383-398.	3.0	106
270	Noradrenergic innervation patterns in three regions of medial cortex: An immunofluorescence characterization. Brain Research Bulletin, 1979, 4, 849-857.	3.1	57

#	Article	IF	Citations
271	Lateralization of catecholaminergic and behavioral response to cerebral infarction in the rat. Life Sciences, 1979, 24, 943-950.	4.4	53
272	Histological and neurochemical effects of fetal treatment with methylazoxymethanol on rat neocortex in adulthood. Brain Research, 1979, 170, 135-155.	2.3	198
273	Rotational behaviour in rats with unilateral striatal kainic acid lesions: A behavioural model for studies on intact dopamine receptors. Brain Research, 1979, 170, 485-495.	2.3	120
274	Dopamine receptors localised on cerebral cortical afferents to rat corpus striatum. Nature, 1978, 271, 766-768.	36.2	405
275	Absence of a relationship between sympathetic neuronal activity and turnover of serum dopamine-?-hydroxylase. Naunyn-Schmiedeberg's Archives of Pharmacology, 1978, 304, 231-236.	3.1	16
276	In situ injection of kainic acid: A new method for selectively lesioning neuronal cell bodies while sparing axons of passage. Journal of Comparative Neurology, 1978, 180, 301-323.	2.0	594
277	The distribution and orientation of noradrenergic fibers in neocortex of the rat: An immunofluorescence study. Journal of Comparative Neurology, 1978, 181, 17-39.	2.0	245
278	Structure-activity relations for the neurotoxicity of kainic acid derivatives and glutamate analogues. Neuropharmacology, 1978, 17, 145-151.	4.2	175
279	Influence of cortico-striatal afferents on striatal kainic acid neurotoxicity. Neuroscience Letters, 1978, 8, 303-310.	2.1	215
280	Neuronal localization of specific brain phosphoproteins. Brain Research, 1978, 156, 345-350.	2.3	38
281	Alterations of muscarinic cholinergic receprtors in the rat striatum after kainic acid injections. Brain Research, 1978, 152, 620-625.	2.3	36
282	Long-term sequelae of striatal kainate lesion. Brain Research, 1978, 152, 626-632.	2.3	78
283	Neuronal mapping with kainic acid. Trends in Neurosciences, 1978, 1, 132-135.	8.8	13
284	Pharmacological augmentation of acetylcholine levels in kainate-lesioned rat striatum. Biochemical Pharmacology, 1978, 27, 2962-2965.	4.6	32
285	Psychiatric Drugs in Medical Practice. Medical Clinics of North America, 1977, 61, 891-905.	2.3	3
286	The immunohistochemical demonstration of noradrenergic neurons in the rat brain: The use of homologous antiserum to dopamine-Î²-hydroxylase. Neuroscience Letters, 1977, 4, 127-134.	2.1	76
287	Neurochemical sequelae of kainate injections in corpus striatum and substantia nigra of the rat. Life Sciences, 1977, 20, 431-436.	4.4	143
288	Striatal lesions with kainic acid: neurochemical characteristics. Brain Research, 1977, 127, 235-249.	2.3	458

#	Article	IF	Citations
289	Inhibitors of GABA metabolism: Implications for Huntington's disease. Annals of Neurology, 1977, 2, 299-303.	5.8	49
290	Biochemical Aspects of Neurotransmission in the Developing Brain. International Review of Neurobiology, 1977, 20, 65-103.	1.8	147
291	Adenylate cyclase activity in chick retina. General Pharmacology, 1976, 7, 349-354.	0.6	17
292	Neurochemical aspects of the ontogenesis of cholinergic neurons in the rat brain. Brain Research, 1976, 118, 429-440.	2.3	561
293	Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea. Nature, 1976, 263, 244-246.	36.2	1,248
294	Subcellular localization of dopamine Î²-hydroxylase and endogenous norepinephrine in the rat hypothalamus. Brain Research, 1974, 65, 475-487.	2.3	40
295	Avoidance conditioning in different strains of rats: Neurochemical correlates. Psychopharmacology, 1973, 31, 25-34.	3.1	40
296	Dopaminergic neurons in explants of substantia nigra in culture. Journal of Neurobiology, 1973, 4, 461-470.	3.1	33
297	Ontogenetic regulation of catecholamine synthesis. Life Sciences, 1973, 13, xxii-xxiii.	4.4	0
298	Tyrosine hydroxylase in rat brainâ€"cofactor requirements, regional and subcellular distribution. Biochemical Pharmacology, 1972, 21, 1935-1944.	4.6	305
299	Rapid axonal transport of tyroxine hydroxylase and dopamine-Î²-hydroxylase. Brain Research, 1972, 44, 701-704.	2.3	34
300	DOPA decarâ˜ylase in the developing rat brain. Brain Research, 1972, 41, 503-506.	2.3	123
301	The Role of Brain Dopamine in Behavioral Regulation and the Actions of Psychotropic Drugs. American Journal of Psychiatry, 1970, 127, 199-207.	8.7	196
302	Uptake and Subcellular Localization of Neurotransmitters in the Brain. International Review of Neurobiology, 1970, 13, 127-158.	1.8	107
303	Section summary and perspectives: Translational medicine in psychiatry. , 0, , 118-128.		0
304	The discovery and development of drugs to treat psychiatric disorders: Historical perspective. , 0, , 1-13.		0
305	Dona Lee Wong (1946â€“2022). Neuropsychopharmacology, 0, , .	5.6	0